Waldencast plc announced the SEC will not pursue action following its investigation into financial restatements and internal controls.
Quiver AI Summary
Waldencast plc announced that the U.S. Securities and Exchange Commission has concluded its investigation into the company's financial practices associated with Obagi Cosmeceuticals, finding no grounds for enforcement action. CEO Michel Brousset expressed satisfaction with the favorable outcome, highlighting the company's full cooperation during the investigation while continuing to focus on business objectives and governance. The investigation, which involved a restatement of financial results and identified weaknesses in internal controls, had been previously disclosed by Waldencast, which voluntarily contacted the SEC on the matter and incurred significant costs in the process. Waldencast aims to establish a leading global beauty and wellness platform by developing and scaling purpose-driven brands.
Potential Positives
- The SEC concluded its investigation without recommending any enforcement action against Waldencast, signaling a favorable resolution to a potentially damaging issue.
- The company's full cooperation with the SEC throughout the investigation may enhance its reputation for transparency and governance.
- This positive outcome allows Waldencast to refocus on its business operations and goals, minimizing distractions from the investigation.
Potential Negatives
- The press release indicates that Waldencast had material weaknesses in its internal control over financial reporting, which raises concerns about the reliability of its financial statements.
- The costs incurred during the SEC investigation for legal and advisory services were substantial, which may affect the company's financial resources and operational focus.
- The investigation itself could negatively impact investor confidence, even though no enforcement action was recommended.
FAQ
What was the outcome of the SEC investigation into Waldencast?
The SEC concluded its investigation without recommending any enforcement action against Waldencast.
Who is the CEO of Waldencast?
Michel Brousset is the Chief Executive Officer of Waldencast.
What led to the SEC investigation of Waldencast?
The investigation was initiated due to the restatement of Waldencast's financial results and internal control weaknesses.
What is the focus of Waldencast plc?
Waldencast aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands.
What is Obagi Medical known for?
Obagi Medical specializes in advanced skincare products targeting various skin issues, backed by over 35 years of research.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$WALD Hedge Fund Activity
We have seen 28 institutional investors add shares of $WALD stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 745,165 shares (-88.9%) from their portfolio in Q4 2025, for an estimated $1,400,910
- MCADAM, LLC removed 45,264 shares (-71.8%) from their portfolio in Q4 2025, for an estimated $85,096
- SQUAREPOINT OPS LLC removed 39,311 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $73,904
- NORTHERN TRUST CORP removed 39,112 shares (-15.7%) from their portfolio in Q4 2025, for an estimated $73,530
- DEUTSCHE BANK AG\ added 31,341 shares (+264.2%) to their portfolio in Q4 2025, for an estimated $58,921
- BLACKROCK, INC. added 28,383 shares (+1.4%) to their portfolio in Q4 2025, for an estimated $53,360
- CIBC ASSET MANAGEMENT INC added 24,642 shares (+inf%) to their portfolio in Q4 2025, for an estimated $46,326
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$WALD Analyst Ratings
Wall Street analysts have issued reports on $WALD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 01/14/2026
- Canaccord Genuity issued a "Buy" rating on 11/25/2025
To track analyst ratings and price targets for $WALD, check out Quiver Quantitative's $WALD forecast page.
$WALD Price Targets
Multiple analysts have issued price targets for $WALD recently. We have seen 3 analysts offer price targets for $WALD in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Susan Anderson from Canaccord Genuity set a target price of $2.0 on 03/16/2026
- Dana Telsey from Telsey Advisory Group set a target price of $2.0 on 03/16/2026
- Sydney Wagner from Jefferies set a target price of $2.0 on 01/14/2026
Full Release
LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“ Waldencast ” or the “ Company ”), a global multi-brand beauty and wellness platform, announced today that it was notified by the staff of the U.S. Securities and Exchange Commission (the “ SEC ”) that they have concluded their investigation of the Company relating to Waldencast’s restatement of its financial results and material weaknesses in its internal control over financial reporting related to historical accounting practices used by Obagi Cosmeceuticals (the “ Investigation ”) and, based on the information available as of the date of the notice, the SEC does not intend to recommend an enforcement action against Waldencast.
“We are pleased with the favorable outcome of the SEC’s investigation,” stated Michel Brousset, Chief Executive Officer of Waldencast. “Throughout the Investigation, we fully cooperated and dedicated significant resources to the process. At the same time, we maintained our focus on executing our business plans, upholding strong governance, and ensuring robust internal controls.”
The Investigation was previously disclosed by the Company in its periodic reports under the Securities Exchange Act of 1934, as amended. As previously disclosed, the Company voluntarily contacted the SEC regarding these matters and has fully cooperated with the SEC throughout the course of the Investigation, incurring substantial legal, advisory and other related costs.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com.
Obagi Medical is an industry-leading, advanced skin care line rooted in research and skin biology, refined with a legacy of over 35 years’ experience. Obagi Medical products are designed to address the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage. More information about Obagi Medical is available on the brand’s website at www.obagi.com.
Founded in 2016, Milk Makeup quickly became a cult-favorite among the beauty community for its values of self-expression and inclusion, captured by its signature “Live Your Look”, its innovative formulas, and clean ingredients. The brand creates vegan, cruelty-free, clean formulas and has its Milk Makeup HQ in Downtown NYC. More information about Milk Makeup is available on the brand’s website at www.milkmakeup.com.
Contacts:
Investors
ICR
Allison Malkin
[email protected]
Media
ICR
Brittney Fraser/Alecia Pulman
[email protected]
